MA vs RNAZ · P/E 38, rev $32.79B vs $5.1M cap
Mastercard Inc (MA) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
RNAZ does not have a complete income-statement cache yet.
MA currently screens at market cap $515.12B and trailing P/E 38.4. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the MA and RNAZ stock pages for the full models.
Not investment advice.